|dc.description.abstract||OBJECTIVE: The aims of this study were to determine the expression of PTEN in endometrial adenocarcinomas (as a potential prognostic indicator before treatment) in imprint smears and to correlate the results with clinicopathologic parameters of primary untreated endometrial cancer patients.
METHODS: One hundred twenty-six patients with endometrial carcinoma were evaluated with samples freshly resected after a total abdominal hysterectomy during a 29-month period. The expression of PTEN was assessed by immunocytochemistry.
RESULTS: One hundred two cases were type I and twenty-four type II endometrial adenocarcinomas. High expression of PTEN was more frequent in type I (42/102) comparatively to type II (6/24) adenocarcinomas, to less advanced and aggressive clinical stage (stage I: 41/79, stage II: 5/13, stage III: 2/19, stage IV: 1/15) as well as in low grade (grade 1: 26/42, grade 2: 20/57) comparatively to high grade (grade 3: 8/27) carcinomas. Moreover, the non-affected from the disease lymph nodes showed high expression of PTEN (in 43.3%) than the affected lymph nodes (in 5.9%). Also, in 45 out of 74 cases with myometrial invasion <1/2, there was positive expression of PTEN in contrast to 12 out of 52 cases with depth of myometrial invasion >1/2.
CONCLUSIONS: Immunocytochemical findings from PTEN stain, in addition to cytomorphologic features, appeared to be a useful marker in the diagnosis and in the postoperative prognosis of endometrial carcinoma in endometrial cytology with imprint smears and that high PTEN expression is related to morphologic features of less aggressiveness tumors.||en